Rausch, C.; Bacher, U.; Rabaglio, M.; Vorburger, C.; Klingenberg, A.; Banz, Y.; Daskalakis, M.; Pabst, T.
Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. J. Clin. Med. 2022, 11, 5378.
https://doi.org/10.3390/jcm11185378
AMA Style
Rausch C, Bacher U, Rabaglio M, Vorburger C, Klingenberg A, Banz Y, Daskalakis M, Pabst T.
Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. Journal of Clinical Medicine. 2022; 11(18):5378.
https://doi.org/10.3390/jcm11185378
Chicago/Turabian Style
Rausch, Christian, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis, and Thomas Pabst.
2022. "Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study" Journal of Clinical Medicine 11, no. 18: 5378.
https://doi.org/10.3390/jcm11185378
APA Style
Rausch, C., Bacher, U., Rabaglio, M., Vorburger, C., Klingenberg, A., Banz, Y., Daskalakis, M., & Pabst, T.
(2022). Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. Journal of Clinical Medicine, 11(18), 5378.
https://doi.org/10.3390/jcm11185378